

April 06, 2026

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Clarification on Financial Results Submission for the period ended September 30, 2025.

With reference to the e-mail dated April 02, 2026 received from the NEAPS portal seeking clarification on Outcome of Board Meeting-Financial Results submitted to the Exchange dated October 17, 2025, we would like to submit as below:

1. Financial results submitted is not as per format prescribed by SEBI - In Balance sheet comparative period data is not given for March, 2025

We would like to clarify that due to inadvertent oversight error, in the Balance sheet section of the financial results; for a comparative period data, we have provided details of the September, 2024 instead of March, 2025. The Balance sheet for the period ended September 30, 2025 have now been with a comparative period data for the period ended March 31, 2025.

2. Machine Readable Form / Legible copy of Financial Results not submitted

With reference to the observation regarding non-submission of the financial results in machine-readable / legible format, we wish to clarify that the financial results for the period ended September 30, 2025 have now been in a machine-readable and searchable PDF format.

A copy of the financial results with the details as abovementioned is annexed as per Annexure-1. We hereby confirm that there is no change in the financial figures of the financial results earlier submitted.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Company Secretary & Compliance Officer)

Place: Surat

Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601

Email: info@zotahealthcare.com

Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zota Health Care Limited** (the "Company") for the quarter and half year ended **September 30, 2025** ("the Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Management's Responsibility

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and

A/401, President Plaza, Near R.T.O. Office, Ring Road, Surat -395001

PH. No. 2474714 / 2474954 E-mail: info.surat@pradeepsinghi.com

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 17/10/2025

Place: Surat

For Pradeep K. Singhi & Associates

Chartered Accountants

FRN : 0126027W

**PRADEEP
KUMAR
SINGHI**

Digitally signed by
PRADEEP KUMAR
SINGHI
Date: 2025.10.17
18:20:02 +05'30'

Pradeep Kumar Singhi

(Partner)

M. No. 200/024612

UDIN: 25024612BMONNN9391

A/401, President Plaza, Near R.T.O. Office, Ring Road, Surat -395001

PH. No. 2474714 / 2474954 E-mail: info.surat@pradeepsinghi.com

Particulars	(Amount ₹ In Lakhs, except per share capital data)					
	Quarter Ended			Half Year Ended		Year Ended
	30-09-2025 (Unaudited)	30-06-2025 (Unaudited)	30-09-2024 (Unaudited)	30-09-2025 (Unaudited)	30-09-2024 (Unaudited)	31-03-2025 (Audited)
I. Revenue from Operations	9942.42	7800.70	5900.92	17743.12	11121.28	25727.61
II. Other Income	326.71	223.39	97.01	550.10	143.89	462.34
III. Total Income	10269.13	8024.09	5997.93	18293.22	11265.17	26189.94
IV. Expenses:						
Cost of Materials Consumed	288.85	490.52	430.72	779.38	709.83	1622.76
Purchases of Stock-in-Trade	4810.83	3442.21	2907.89	8253.04	5252.57	15530.50
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	336.39	536.90	215.20	873.29	775.43	(1614.25)
Employee Benefit Expenses	1025.36	997.58	729.09	2022.94	1373.26	3114.97
Finance Costs	8.67	3.68	51.91	12.35	93.84	105.59
Depreciation / Amortisation and Depletion Expense	91.04	79.68	73.35	170.72	141.00	317.11
Other Expenses	2400.92	1618.96	1293.73	4019.89	2391.02	5928.92
Total Expenses	8962.07	7169.54	5701.91	16131.61	10736.94	25005.61
V. Profit before Exceptional items and tax from continuing operations (III-IV)	1307.05	854.56	296.02	2161.61	528.23	1184.33
VI. Exceptional Items	-	-	-	-	-	-
VII. Profit/(loss) before tax	1307.05	854.56	296.02	2161.61	528.23	1184.33
VIII. Tax Expense:						
(1) Current tax	332.17	223.68	84.74	555.85	149.45	338.13
(1.1) I.T. & DD Tax Provision Created Short/ excess	-	-	-	-	-	(2.49)
(2) Deferred Tax	15.97	(40.44)	23.91	(24.47)	14.84	13.03
IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	990.85	590.44	235.19	1581.29	393.62	861.72
X. Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XI. Tax Expense of discontinued Operations	-	-	-	-	-	-
XII. Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-	-	-
XIII. Profit/ (Loss) for the period	990.85	590.44	235.19	1581.29	393.62	861.72
XIV. Other Comprehensive Income						
A (i) Items that will not be reclassified to Statement of profit and loss	0.00	(16.09)	(20.58)	(16.09)	(9.96)	19.11
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	0.00	4.05	5.18	4.05	2.51	(4.81)
B (i) Items that will be reclassified to Statement of profit and loss	0.00	-	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-	-	-
Other comprehensive income for the period, net of tax	-	(12.04)	(15.40)	(12.04)	(7.46)	14.30
Total comprehensive income for the period (XIII + XIV)	990.85	578.40	219.79	1569.24	386.17	876.01
Paid-up Equity Share Capital	3064.38	2976.66	2740.76	3064.38	2740.76	2863.50
Other Equity	-	-	-	-	-	28873.37
Earnings per equity share of face value of ₹ 10 each						
(1) Basic (in ₹)	3.27	2.03	0.89	5.30	1.48	3.16
(2) Diluted (in ₹)	3.12	1.88	0.82	5.05	1.38	2.91

* denotes figures less than a lakh
For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


Company Secretary
Ashvin Variya
Date: 17-10-2025
Place : Surat


Chief Financial Officer
Viral Mandviwala



For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep KUMAR SINGHI
Date: 2025.10.17 18:20:29 +05'30'

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

**The Board of Directors of
Zota Health Care Limited**

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the **quarter and half year ended September 30, 2025** ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Regulation").

Management's Responsibility

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- a. Zota Health Care Limited (Parent)
- b. Zota Healthcare Lanka (Pvt) Ltd (Wholly Owned Subsidiary)

A/401, President Plaza, Near R.T.O. Office, Ring Road, Surat -395001

PH. No. 2474714 / 2474954 E-mail: info.surat@pradeepsinghi.com

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

- c. Davaindia Health Mart Limited (Wholly Owned Subsidiary)
- d. Zota Nex Tech Limited (Wholly Owned Subsidiary)
- e. Everyday Herbal Beauty Care Private Limited (Subsidiary)
- f. Everyday Herbal Beauty And Wellness Care Private Limited (Subsidiary)

Conclusion

Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

We did not review the interim financial statements of the subsidiaries included in the consolidated unaudited financial results that reflect total assets of Rs. 35028.16 Lakhs as at September 30, 2025, total revenues of Rs. 6432.52 Lakhs and Rs.11681.31 Lakhs, total net loss of Rs. 2666.72 Lakhs and Rs.4628.24 Lakhs and total comprehensive loss of Rs. 2666.72 Lakhs and Rs.4626.70 Lakhs, respectively for the quarter and half year ended September 30, 2025, and net cash flows of Rs. 281.57 Lakhs for the half year ended September 30, 2025 as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For Pradeep K. Singhi & Associates
Chartered Accountants
FRN : 0126027W

Date: 17/10/2025

Place: Surat

PRADEEP
KUMAR SINGHI

Digitally signed by
PRADEEP KUMAR SINGHI
Date: 2025.10.17
18:20:44 +05'30'

Pradeep Kumar Singhi
(Partner)

M. No. 200/024612


UDIN: 25024612BMONNO4146

A/401, President Plaza, Near R.T.O. Office, Ring Road, Surat -395001

PH. No. 2474714 / 2474954 E-mail: info.surat@pradeepsinghi.com

healthcare ltd.		(Amount ₹ in Lakhs, except per share capital data)					
		Quarter Ended			Half Year ended		Year Ended
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
Particulars		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from Operations	12894.82	10358.26	6727.58	23253.08	12357.65	29297.48
II.	Other Income	163.65	87.61	54.27	251.26	56.06	206.80
III.	Total Income	13058.47	10445.87	6781.86	23504.33	12413.71	29504.28
IV.	Expenses:						
	Cost of Materials Consumed	288.85	490.52	430.72	779.38	709.83	1622.76
	Purchases of Stock-in-Trade	5847.62	4185.61	2905.91	10033.22	5227.53	16257.53
	Changes in Inventories of Finished Goods, Work-In-Progress and Stock-in-Trade	(891.91)	(162.85)	(211.11)	(1054.77)	(177.75)	(4149.96)
	Employee Benefit Expenses	3819.72	3317.31	2006.36	7137.03	3631.01	8606.62
	Finance Costs	382.82	323.90	285.33	706.72	575.13	1078.34
	Depreciation / Amortisation and Depletion Expense	1850.79	1467.84	951.23	3318.63	1753.58	4319.61
	Other Expenses	3198.48	2132.02	1682.72	5330.50	3179.91	7533.82
	Total Expenses	14496.38	11754.35	8051.15	26250.72	14899.25	35268.71
V.	Profit before Exceptional Items and tax from continuing operations (II-IV)	(1437.91)	(1308.48)	(1269.30)	(2746.39)	(2485.54)	(5764.43)
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit/(loss) before tax	(1437.91)	(1308.48)	(1269.30)	(2746.39)	(2485.54)	(5764.43)
VIII.	Tax Expense:						
	(1) Current tax	317.80	244.25	84.74	562.05	149.45	338.13
	(1.1) I.T. & DD Tax Provision Created Short/ excess	-	-	-	-	-	(2.49)
	(2) Deferred Tax	136.33	174.94	135.94	311.28	144.51	426.19
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	(1619.38)	(1377.79)	(1218.10)	(2997.17)	(2490.49)	(5673.89)
X.	Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XI.	Tax Expense of discontinued Operations	-	-	-	-	-	-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-	-	-
XIII.	Profit/ (Loss) for the period	(1619.38)	(1377.79)	(1218.10)	(2997.17)	(2490.49)	(5673.89)
XIV.	Other Comprehensive Income						
	A (i) Items that will not be reclassified to Statement of profit and loss	-	(14.04)	(22.78)	(14.04)	(10.39)	40.31
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	-	3.53	5.73	3.53	2.62	(10.11)
	B (i) Items that will be reclassified to Statement of profit and loss	-	0.01	(0.01)	-	(0.07)	(0.05)
	(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-	0.02	0.01
	Other comprehensive income for the period, net of tax	(30.67)	(10.51)	(17.06)	(10.51)	(7.83)	30.16
	Total comprehensive income for the period (XIII + XIV)	(1619.38)	(1388.29)	(1235.16)	(3007.67)	(2498.32)	(5643.73)
	Profit attributable to:						
	Owners of the parent	(1594.88)	(1431.58)	(1210.24)	(3026.46)	(2482.63)	(5639.84)
	Non-controlling interest	(24.49)	53.79	(7.86)	29.30	(7.86)	(34.05)
	Other comprehensive income attributable to:						
	Owners of the parent	0.36	(12.08)	(17.06)	(11.72)	(7.83)	30.16
	Non-controlling interest	(0.36)	1.57	-	1.22	-	-
	Total Comprehensive income attributable to:						
	Owners of the parent	(1594.53)	(1443.66)	(1227.30)	(3038.18)	(2490.46)	(5609.68)
	Non-controlling interest	(24.85)	55.37	(7.86)	30.51	(7.86)	(34.05)
	Paid-up Equity Share Capital	3064.38	2976.66	2740.76	3064.38	2740.76	2863.50
	Other Equity	-	-	-	-	-	19504.98
	Earnings per equity share of face value of ₹ 10 each						
	(1) Basic (In ₹)	-5.26	(4.92)	(4.57)	(10.14)	(9.36)	(20.68)
	(2) Diluted (In ₹)	(5.02)	(4.56)	(4.23)	(9.66)	(8.69)	(19.06)

* denotes figures less than a lakh
For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)




Company Secretary
Ashwin Variya
Date: 17-10-2025
Place : Surat


Chief Financial Officer
Viral Mandviwala

For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep K. Singhi
KUMAR SINGHI

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

ZOTA HEALTH CARE LIMITED
Standalone and Consolidated Unaudited Statement of Assets and Liabilities

(Amount ₹ in Lakhs)

Particulars	Standalone		Consolidated	
	As at 30th September, 2025 Unaudited	As at 31st March, 2025 Audited	As at 30th September, 2025 Unaudited	As at 31st March, 2025 Audited
ASSETS				
(1) Non-Current Assets				
Property, plant and equipment	1109.50	845.61	7593.49	5598.94
Right-of-use assets	-	-	16211.75	12538.11
Intangible Assets	398.49	379.62	417.84	401.37
Capital work-in-progress	651.48	557.58	651.48	557.58
Intangible assets under development	-	-	858.02	90.25
Financial Assets				
(i) Investments	20440.46	11623.96	9228.37	5435.30
(iii) Loans	9569.81	5921.96	11.02	11.02
Deferred tax assets (Net)	(8.82)	15.66	1176.50	865.22
Other Non-current assets	-	-	-	-
Total Non-Current assets	32160.91	19344.38	36148.46	25497.79
(2) Current Assets				
Inventories	5242.46	5955.53	11783.36	10568.38
Financial Assets				
(i) Trade Receivables	12451.37	10303.88	5814.18	4050.15
(ii) Cash and Cash Equivalents	0.63	0.52	417.26	213.21
(iii) Bank balance other than cash and cash equivalents	122.63	134.46	214.51	148.70
(iv) Loans	1320.43	1793.78	4060.50	1699.06
Other Current Assets	377.79	439.73	2152.52	1736.76
Total Current assets	19515.31	18627.91	24442.33	18416.26
Total Assets	51676.22	37972.29	60590.79	43914.05
EQUITY AND LIABILITIES				
(1) Equity				
(i) Equity Share capital	3064.38	2863.50	3064.38	2863.50
(ii) Other Equity	42518.94	28873.37	28510.11	19504.98
Non-controlling interest	-	-	311.51	347.00
Total Equity (Refer Note 1)	45583.32	31736.87	31886.01	22715.48
(2) Liabilities				
Non-Current Liabilities				
Financial Liabilities				
(i) Borrowings	-	-	503.92	499.48
(ii) Lease liabilities	-	-	13187.45	10255.49
Provisions	242.30	179.34	602.53	382.21
Total non-current liabilities	242.30	179.34	14293.90	11137.19
Current liabilities				
Financial Liabilities				
(i) Borrowings	160.41	20.46	163.91	60.95
(ii) Lease liabilities	-	-	4287.88	3144.45
(ii) Trade payables	-	-	0.00	-
- Total outstanding dues of micro enterprises and small enterprises	1634.59	1248.17	1715.46	1248.17
- Total Outstanding dues of Creditors other than micro enterprises and small enterprises	2605.83	3374.44	4533.80	2991.91
Other Current liabilities	193.31	759.56	806.17	1008.34
Provisions	1256.47	653.45	2903.68	1607.55
Total current liabilities	5850.60	6056.08	14410.88	10061.38
Total Liabilities	6092.91	6235.41	28704.78	21198.57
Total Equity and Liabilities	51676.22	37972.29	60590.79	43914.05

For and on behalf of the Board

HIMANSHU MUKTILAL ZOTA
Digitally signed by HIMANSHU MUKTILAL ZOTA
Date: 2025.01.20 17:38:34 +05'30'

(Whole Time Director)

Himanshu M. Zota

(DIN: 01097722)



Company Secretary

Ashvin Variya

Date: 17-10-2025

Place : Surat



Chief Financial Officer

Viral Mandviwala



For Pradeep K. Singhi & Associates

Chartered Accountants

Firm No. 0126027W

PRADEEP KUMAR SINGHI

Digitally signed by PRADEEP KUMAR SINGHI
Date: 2025.01.20 17:43:27 +05'30'

Pradeep Kumar Singhi

(Partner)

M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLCO38352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

	healthcare ltd.	Consolidated		Standalone	
		Half year ended 30-09-2025 (Unaudited)	Half year ended 30-09-2024 (Unaudited)	Half year ended 30-09-2025 (Unaudited)	Half year ended 30-09-2024 (Unaudited)
A	CASH FLOW FROM OPERATING ACTIVITIES				
	Net Profit Before Tax as per Statement of Profit and Loss	-2746.39	-2485.54	2161.61	528.23
	Adjusted for:				
	Exceptional items	-	-	-	-
	Depreciation / Amortisation and Depletion Expense	3318.63	1753.58	170.72	141.00
	Employee stock option expense	138.72	28.45	138.72	28.45
	Interest on Fixed Deposits	-186.91	-47.65	-486.04	-135.48
	Finance Costs	570.55	462.93	0.00	26.77
	Operating Profit before Working Capital Changes	1094.60	-288.22	1985.01	588.96
	Adjusted for:				
	Trade Payables	2009.17	-356.79	-382.19	415.94
	Provisions - Current Liabilities	1282.08	543.77	586.92	246.04
	Provisions - Non-Current	220.31	104.51	62.96	35.29
	Current Liabilities	-202.17	137.34	-566.25	101.89
	Trade Receivables	-1764.03	-164.43	-2147.49	-3735.39
	Loans	-2361.44	218.60	473.36	-1323.09
	Inventories	-1214.98	-1091.45	713.07	624.42
	Other Current Assets	-415.76	-109.34	61.93	-113.77
	Changes in Working Capital	-2446.82	-717.79	-1197.68	-3748.67
	Cash Generated from Operations	-1352.22	-1006.01	787.34	-3159.71
	Taxes Paid	-558.53	-146.84	-551.80	-146.95
	Net Cash Flow from/(Used in) Operating Activities (A)	-1910.74	-1152.85	235.54	-3306.65
B	CASH FLOW FROM INVESTING ACTIVITIES				
	Purchase of Intangible Assets	-4.26	-67.01	-4.26	-67.01
	Decrease in Long Term Loans & Advances	-	-	-3647.86	-160.87
	Interest on Fixed Deposits	186.91	47.65	486.04	135.48
	Interest - others	-	-26.77	-	-26.77
	Proceeds from disposal of Property, Plant and Equipment and Intangible Assets	-	-	-	-
	Purchase of Tangible Assets	-3672.15	-1511.42	-543.10	-57.41
	Non-current Investments	-3793.07	-3944.84	-8816.50	-4386.48
	Net Cash Flow (Used in) Investing Activities (B)	-7282.57	-5502.39	-12525.68	-4563.06
C	CASH FLOW FROM FINANCING ACTIVITIES				
	Add: Adjustment for				
	Proceeds from Issue of Equity Share Capital	200.88	156.03	200.88	156.03
	Increase in Securities Premium Reserve	11937.60	6370.65	11937.60	6370.65
	Decrease in short-term Borrowings	107.39	-1253.34	139.95	-1467.67
	Money received against Share warrants	-	2845.15	-	2845.15
	Purchase of non-controlling interest shares	-99.00	-	-	-
	Principal payment of lease liability	-2113.15	-895.93	-	-
	Interest payment of lease liability	-570.55	-436.17	-	-
	Dividend Paid	-	-	-	-
	Net Cash Flow from / (Used in) Financing Activities (C)	9463.17	6786.39	12278.43	7904.15
	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	269.86	131.15	-11.72	34.44
	Opening Balance of Cash and Cash Equivalents	361.91	100.47	134.99	14.28
	Closing Balance of Cash and Cash Equivalents	631.77	231.62	123.27	48.72

The accompanying notes are an integral part of the financial statements.
As per our report of even date

For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(CIN : 01097722)


Company Secretary
Ashvin Variya


Chief Financial Officer
Virel Mandwani



For Pradeep K. Singh & Associates
Chartered Accountants
Firm No. 0126027W

Digitally signed by
PRADEEP KUMAR SINGHI
KUMAR SINGHI
Date: 2025.09.27 16:23:15
+05'30'

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Date: 17-10-2025
Place: Surat

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122



zota[®]
healthcare ltd.

Notes:

1. The above financial results for the quarter and half year ended September 30, 2025 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on October 17, 2025.
2. The financial results have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.
3. The Statutory Auditors have carried out Limited Review of the financial results for the quarter and half year ended September 30, 2025.
4. During the quarter, upon receipt of balance 75% amount i.e. Rs. 381.75/- per warrant of the warrants issue price, the Board of Directors of the Company has issued equity shares upon conversion of warrants as below:

Date of Allotment	No. of Equity Shares Issued
July 02, 2025	3,40,829
July 21, 2025	2,10,510
August 20, 2025	14,734
September 13, 2025	1,61,158

5. During the quarter, upon receipt of balance 75% amount i.e. Rs. 615.00/- per warrant of the warrants issue price, the Board of Directors of the Company has on September 13, 2025 allotted 1,50,000 equity shares upon conversion of warrants.
6. The company has evaluated its Operating segment in accordance with Ind As 108 and has concluded that it is engaged in a single operating segment.
7. During the quarter, as a part of backward integration the Company has further acquired 6,60,000 equity shares of 9.98% stake in Everyday Herbal Beauty Care Private Limited ("EHBCPL") from Mr. Rajesh Vanechand Kubadiya, Director of EHBCPL, Subsidiary of the Company. Consequent to the above acquisition, the Company has a shareholding of 65.98% in EHBCPL.
8. The consolidated results include the result of following companies:
 - A) Wholly owned subsidiaries:
 - i) Zota Healthcare Lanka (Pvt) Ltd
 - ii) Davaindia Health Mart Limited
 - iii) Zota Nex Tech Limited
 - B) Subsidiaries:
 - i) Everyday Herbal Beauty Care Private Limited
 - ii) Everyday Herbal Beauty and Wellness Care Private Limited
9. In the consolidated financial results, the Company has adopted Ind As 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 16,211.75 lakhs and a corresponding Lease Liability of Rs. 17,475.33 lakhs as at September 30, 2025. The impact of this on the consolidated profit for the quarter and half year ended September 30, 2025 is Rs. 235.69 lakhs and Rs. 423.10 lakhs respectively.
10. Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotchealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

